TerminatedNCT03230097

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Medication studyAges 16–30Multiple countriesSchizophrenia

The study in practice

Understand this study

Listed age limits: 16 years to 30 years.

Listed locations: Culver City and 32 more locationsSee all locations and recruitment
Study phase: Phase 2

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: September 29, 2017

Recruitment status: Terminated
Enrollment listed in the registry: 50
Sponsor: Boehringer Ingelheim
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Drug
Study phase: Phase 2
Locations: United States, Canada, United Kingdom, ...
Age range: From 16 Years to 30 Years
Official registry ID: NCT03230097
Official title: Show the full official title
A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.

Terminated

Culver City, United States · San Diego, United States · New Haven, United States

29 more locations

FAQ

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Does this study involve medication?

Yes. The study involves medication, including BI 409306 and Placebo.

Who can participate?

Listed age limits: 16 years to 30 years.

Is this study still recruiting?

The registry lists this study as terminated.